EMA Application withdrawn: Abilify MyCite (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The EMA has withdrawn the application for Abilify MyCite (aripiprazole) by Otsuka Pharmaceutical Netherlands B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Abilify MyCite (aripiprazole)

Snippet

Status: Application withdrawn. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Otsuka Pharmaceutical Netherlands B.V.